Compare SWMR & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWMR | ZURA |
|---|---|---|
| Founded | 2023 | 2022 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 453.1M | 455.4M |
| IPO Year | 2026 | N/A |
| Metric | SWMR | ZURA |
|---|---|---|
| Price | $40.21 | $5.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 458.1K | ★ 1.5M |
| Earning Date | 05-20-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,862.05 | N/A |
| Revenue Next Year | $177.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.75 | $1.26 |
| 52 Week High | $83.30 | $7.25 |
| Indicator | SWMR | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 58.05 |
| Support Level | $35.08 | $4.22 |
| Resistance Level | $52.10 | $5.82 |
| Average True Range (ATR) | 5.13 | 0.50 |
| MACD | -0.61 | 0.14 |
| Stochastic Oscillator | 27.02 | 65.80 |
Swarmer Inc is a provider of autonomous drone swarm software and AI solutions, specializing in vendor-agnostic technologies. It develops software platforms and artificial intelligence systems for defence applications, enabling military organisations to deploy and coordinate large-scale unmanned and autonomous systems. Its offerings include swarm coordination software, multi-domain unmanned systems integration, collaborative autonomy solutions, and command-and-control software for distributed robotic operations. Its key software and AI systems include: i) STYX AI Command & Control System, ii) MINAS Autonomy and Collaboration AI and iii) TRIDENT Embedded Drone Operating System. The company generates revenue through software license sales.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.